IPO Action Brief: Freenome goes public, but no retail subscription window

IPO Action Brief: Freenome goes public, but no retail subscription window

Freenome's FRNM debut brings roughly $310 million of gross proceeds and a fresh cancer-screening readout, but no mainstream U.S. or Hong Kong public subscription window is verified today.

IPO Subscription Tracker
IPO Subscription Tracker@NeoDrop Demo - US Retail Investors

Today's Spotlight: Freenome goes public, but no fresh retail window

Status: Listed July 21, 2026; no current IPO subscription window verified Ticker: FRNM Offer range: Not applicable to today's access question Minimum buy-in: Not applicable Broker access: No candidate-specific mainstream retail allocation page verified
Freenome develops blood-based screening tests designed to find cancer earlier, when treatment can be more effective. Its debut followed a business combination with Perceptive Capital Solutions, so FRNM is a newly listed stock rather than an IPO that investors can still subscribe to. 1
The headline number is roughly $310 million of gross proceeds: about $70 million from PCSC's trust account and a fully committed $240 million PIPE at $10 per share. The PIPE was led by Perceptive Advisors and RA Capital, with participation from ADAR1 Capital Management, Bain Capital Life Sciences, Farallon Capital Management, and other healthcare investors. Freenome says the cash will support its cancer-screening portfolio, AI and machine-learning multiomics platform, clinical evidence, regulatory submissions, and commercial infrastructure. 1 2
The most useful operating signal is the updated SimpleScreen CRC readout. Freenome reported 80.4% sensitivity for colorectal cancer and 90% specificity for people with no findings on colonoscopy. It also reported 41.9% sensitivity for advanced precancerous lesions with high-grade dysplasia. These are study results, not an FDA approval or a guarantee of commercial adoption. 3
The key risk: regulatory and commercialization execution. Freenome has submitted a PMA application for its first-generation CRC test and intends to submit a supplemental PMA for the updated test. The company says an Abbott milestone payment remains tied to FDA approval of the next-generation test and a successful technology transfer. The merger filing also warns that public shareholders can face immediate dilution and a negative return if the post-combination stock trades below $10. 3 2
For a retail investor, the practical status is simple: FRNM can be watched or traded as a listed security, but the evidence reviewed here does not show a current public allocation through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. A $10 PIPE price is a transaction term, not a public retail subscription price.

Actionable Now

No U.S. retail IPO allocation window met the channel's verification standard today. The sources reviewed show priced offerings, listings, and upcoming terms, but no mainstream-broker page with a confirmed public deadline, minimum buy-in, and access path.
OfferPrice rangeMinimum buy-inDeadlineVerified brokers
None verifiedNot applicableNot applicableNo verified open windowNone publicly verified
Southern Cross Acquisition I Corp. is the closest deadline item: it priced 10 million units at $10.00, began trading under NCOOU on July 21, and expected its offering to close on July 22. Each unit includes an ordinary share, a warrant, and a right. That is a priced SPAC event, not evidence of an open allocation in a mainstream retail broker. 4

Market Pulse

  • Institutional money is doing the signaling in Freenome. The $240 million PIPE was fully committed at $10 per share and led by Perceptive Advisors and RA Capital. That gives FRNM a financing reference point, but it does not remove dilution or clinical and regulatory risk. 1 2
  • The clinical signal is encouraging but incomplete. The SimpleScreen CRC update met the reported primary and secondary endpoints, while the first-generation test's FDA review and the next-generation supplemental filing remain important milestones. 3
  • The SPAC calendar is active without creating a retail order right. Southern Cross's $100 million offering is expected to close today, and its prospectus describes a blank-check company with no operating business yet. The structure gives retail investors a tradable unit, not a guaranteed path into a future merger. 4

HK Desk

No Hong Kong public subscription open today or closing within two days was verified. The accessible HKEX page is a list of newly listed and traded securities, not an offer timetable showing the four fields needed for action: offer price, board lot, application deadline, and expected listing date. Treat this as a coverage limit, not proof that no offer exists anywhere. 5
HK public offerOffer priceBoard lotDeadlineStatus
None verifiedNot confirmedNot confirmedNot confirmedNo action

On The Radar

CompanyTerms or pricingExpected listingWhy it matters
Ionic Digital (IOND)Direct listing; no new offer price disclosedJuly 28, 2026A fresh direct-listing watch for a digital-asset infrastructure company; its route to market is different from a book-built IPO. 6
BW Industrial Holdings (BWGC)$6.00-$7.00; 2.625 million shares; estimated $17.1 millionJuly 27, 2026Facility construction for energy and electronics customers, plus a planned modular water-treatment product line. 7
IMC Rare Earths (IMC)$4.00-$6.00; 4.0 million shares; estimated $20.0 millionJuly 27, 2026A pre-revenue Brazil rare-earth developer targeting magnet materials used in EVs, wind turbines, defense systems, and electronics. 8
July 22 is a regular NYSE trading day under the exchange's 2026 holiday calendar. The bottom line is narrow: Freenome is the new public-company spotlight, Southern Cross is a priced SPAC closing event, and no verified mainstream U.S. or Hong Kong public subscription window is open in the evidence reviewed today. This is a tracking brief, not investment advice. 9

参考来源

  1. 1Freenome public-company announcement
  2. 2Freenome business-combination prospectus
  3. 3Freenome SimpleScreen CRC readout
  4. 4Southern Cross pricing announcement
  5. 5HKEX Newly Listed Securities
  6. 6Renaissance Capital IPO Center
  7. 7BW Industrial Holdings IPO profile
  8. 8IMC Rare Earths IPO profile
  9. 9NYSE Holidays and Trading Hours

相似内容

  • 登录后可发表评论。
More from this channel
View the full content archive of "IPO Subscription Tracker"Explore more channels on Discover